Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma

Abstract

A decision analytic model was constructed to assess the cost–effectiveness of obinutuzumab plus bendamustine followed by obinutuzumabmaintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost–effectiveness than the conventional therapies. Survival outcomes, quality of life of progression free survival, and subsequent treatment costs for progressive disease were the main drivers of the cost– effectiveness of O-B-O. The cost–effectiveness proportions of O-B-O relative to conventional therapies under the recommended cost–effectiveness threshold ranged from 61.0% to 99.9%. Thus, O-B-O was highly cost-effective for treating patients with rrFL in China compared with conventional therapies.

Keywords

• china
• cost–effectiveness
• healthcare payers
• obinutuzumab
• relapsed and refractory follicular lymphoma